• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
* * * * * 1 votes

Schizophrenia self-treatment: Nootropics/"alternatives" for positive and negative symptoms

schizophrenia alternative medication self-medication self-treatment

  • Please log in to reply
92 replies to this topic

#91 mag1

  • Guest
  • 1,090 posts
  • 137
  • Location:virtual

Posted 19 September 2024 - 01:37 AM

I hope readers of the thread have found my comments to be helpful.

I will elaborate on my previous post with additional insights that have occurred to me.

 

Number 1:   Polygenics of Schizophrenia

 

Being able to access full genome polygenic scores for a range of human traits is a game changer. This is all the more true in schizophrenia as the onset is

typically at a fairly early age and people are often entirely unprepared. Personally I was at a complete loss to explain what was happening to me --

Even a few months before onset, I had no idea what was about to happen. That's how medical problems have always been for us -- something would go wrong -- we would all

load up into the minivan and rush on the freeway to the nearest mega-hospital's ER. This is not the most economically or medically efficient way to cope with medical

crises, though it has not been overly obvious to us how else to approach them.

 

However, now with our full genome of polygenic scores with hundreds of polygenic scores all of our medical issues have been revealed to us. 

We will already know what is wrong before the emergency happens and can plan so that we will never have medical emergencies again. We have already spent

countless years researching the most relevant of our medical problems. In the past, medical emergencies made health care very demand inelastic for us -- You have

a medical problem? Hand over your wallet! With current genetic technology this logic is rapidly evolving more to the point of us haggling over price perhaps years before we

even need medical services. This type of logic now applies to the most expensive aspects of our medical needs involving chronic type illnesses. 

 

One might guess that if I had been genotyped at birth with a comprehensive psychchip that knowing my genetic risk for schizophrenia would have been extremely useful for

my parents to chart my future. If I had been told 10 years ahead of onset, then I could have been extremely well-prepared for what would happen. 10 years of extensive research could

have made me a near expert in schizophrenia. Having 20 years notice before any symptoms emerged would offer a truly massive advantage. We could have consulted with leading schizophrenia

experts -- if necessary we could have been pre-prescribed anti-psychotics so they were right on the shelf waiting for use-- perhaps we could have used an online app that could identify

the very earliest sign of positive symptoms and take immediate corrective action -- possibly we could have enlisted the community to help us spot very slight signs of onset -- possibly have

pre-arranged a leave of absence from school/work when symptoms emerged. My suspicion is that using these strategies and possibly others, onset would be detected within days and decline

into some minimally functioning state would not occur. As it was, we never were given an explicit schizophrenia diagnosis (that was only revealed with the polygenic scores) and at best all of us

only had a vague general kindergarten level concept of what the illness might be like. With years of pre-warning we could have studied multiple 1,000 page textbooks on schizophrenia.

 

However, this level of preparation is still not how schizophrenia management is described even in modern abnormal psych textbooks. Instead they still speak of the typical patients as usually a student (perhaps last year of

high school or first year of college) who has been in psychological decline -- often for months -- and then there is some sort of psychiatric emergency and then a rush in a mini-van to the nearest

mega-hospital's ER. The close family usually are the last to know and they often have no idea how to cope with a diagnosis of their children. That is roughly my memory. It was then a great mystery for friends

and family and the community for what was happening. Getting the family involved at birth reasonably would make a profound difference.

 

 

Notably one of the important considerations here is that polygenic transmission will not run true over generations. If it were a simple matter of inheriting a dominant trait, then at least one of the parents

would have already experienced the same phenotypic schizophrenia so would have developed a lifetime of coping skills. Yet, with polygenic transmission it is no longer as clear whether either parent had

ever been at clinical risk. There might then be a void of coping strategies. Even if there were family history it is not entirely clear whether this knowledge would be offered to the children. With my family I am

very unclear about the level of understanding of the illness -- from what I have observed there was near total anosognosia. Anosognosia seems almost uniquely diagnostic for schizophrenic illness.

 

Also with an especially weird type of illness as schizophrenia the type of assortative mating that will ensue largely guarantees that it will not be simple uncomplicated schizophrenia. There will probably be

multiple other behavioral phenotypes involved. That was true for me. My scans reported roughly 4-5 other traits that combine with the schizophrenia. My assessment is that the schizophrenia is probably the least

of my worries -- it has been silent for many years.

 

 

Number 2:   Embryo Selection?

 

The above discussion does suggest that an even more powerful approach to schizophrenia management would be to simply continue with polygenic selection even before birth. One might imagine

an initial round of genetic screening of mates and then a round of embryo selection. Such selection would rapidly remove all human genetic illness and problematic traits in a single generation.

However, I am not sure whether I would accept such use of genetic technology. There is this simple mindedness of such a plan that avoids a range of possible problems that could arise in a near

clonal population. It does nonetheless highlight how important it is that we soon effectively resolve problems such as schizophrenia -- if this is not done soon then we will soon have a future clone 

world with all of the risks that this could entail. 


Edited by mag1, 19 September 2024 - 01:45 AM.


#92 mag1

  • Guest
  • 1,090 posts
  • 137
  • Location:virtual

Posted 25 September 2024 - 02:59 AM

Up till this point my perspective on schizophrenia was that establishment medicine largely has not been overly effective in managing it. The anti-psychotics that we have have substantial side effects, we are unable to more specifically delineate endophenotypes, the environment typically is not optimized for people at high risk ... -- it seemed that we were not that far removed from the primitive days of early 20th century mental health care. However, I have been reading up on the latest in schizophrenia research over the last few days and I was pleasantly surprised to see the advances that have occurred over the last quarter century.

 

KarXT, a new generation of anti-psychotic which is a muscarinic receptor agonist instead of targeting dopamine D2 receptors as first and second generation anti-psychotics do, could be approved by the FDA within the next 2 days!!! This is the first new class of anti-psychotics in over 70 years; it has greatly reduced side effects! With current anti-psychotic treatment we have legions of homeless people in our major cities -- many of whom suffer from schizophrenic illness and who largely are treatment non-compliant because of the serious side effects. KarXT, without these side effects could transform schizophrenic care. Possibly over the next year we might witness a therapeutic revolution in schizophrenia.

 

Without getting bogged down in the trial details it is nonetheless disappointing that the registry trials for KarXT chose to compare against inactive placebo. Isn't standard of care always the ethical comparator? The idea could be that even if a new treatment were not superior to standard of care on the topline, there could still be justifications for approval based upon reduced side effects, etc.. This would clearly seem to apply with current anti-psychotics as so many patients become non-compliant because of the side effects. The old story is that the best anti-psychotic is not the one that has the biggest topline, but is the one patients actually remain compliant with.

 

Another exciting development is a new biomarker test for schizophrenia hallucinations and delusions from MindX. The current DSM-V standard of phenotype diagnosis is very inadequate. Often one has the impression that clinicians are merely pretending to go through a process, while they have preset conceptions of what the results will be -- that was my personal impression. Giving a cognitive test while one is recovering from psychosis would seem a laughably uninformative measure -- clinicians then are constructing their own narrative that does not accurately inform clinical decisions. For me I think the correct approach would be more about assessing pre-onset functioning as the baseline.

 

Yet, with the new objective blood tests, clinicians will need to be much more observant and will need to discard their biases. They will no longer be able to merely assume that hallucinations and delusions are present because the objective biomarker test would be able to independently determine this. Interestingly, the blood tests appear to be quite powerful in pointing patients to the exact treatments that will help them. This is because the biomarkers measured in the blood appear to be causal. So if they found that biomarker A was high then they could suggest Treatment A as a specific treatment to manage this biomarker. There were extremely positive comments by doctors on the MindX website related to how this pharmacofeedback effect was helpful for their patients. As it is now, patients receive treatments that may or may not help and often times the patients become discouraged and become treatment non-compliant before they ever reach their first response. This new feedback approach could be very powerful. The reports mentioned a range of treatments besides the standard anti-psychotics that could help some patients including lithium, omega-3 fatty acids etc. so we could see more of a polypharmacy strategy emerge with potentially much better results. I am quite envious of this new MindX biomarker approach because I know how helpful it would have been for me. When you are at super high polygenic risk as I am -- then having a blood biomarker test could be super powerful. For me, I would have wanted to give it right around when I was ~17.5 years old. That would have been so perfect -- that seems almost the exact time i wold predict early symptoms wold be detectable on the biomarker screen. Having an objective test that would be understandable by me, my parents and knowledgeable would probably have been a game changer as it was I am not entirely whether anyone clearly understood what was happening.

 

I have also updated myself with the latest GWAS. It is somewhat slow going, though they are now up to ~75,000 patients in the latest GWAS. These are surprisingly small numbers considering the enormous costs imposed by schizophrenia -- yet the numbers are gradually moving upwards. With these GWAS, typically what we have seen is that when you move beyond 1 million patients (perhaps 5 million) the entire genetic architecture unlocks. There would then be a near complete molecular understanding of the molecular basis of the illness.Clearly that would be profoundly valuable in finding ways to actually treat it.

 

There is a lot of great news out there for schizophrenia that could potentially have a transformative effect over the next year or two.       


Edited by mag1, 25 September 2024 - 03:46 AM.


sponsored ad

  • Advert
Advertisements help to support the work of this non-profit organisation. To go ad-free join as a Member.

#93 mag1

  • Guest
  • 1,090 posts
  • 137
  • Location:virtual

Posted 26 September 2024 - 09:42 PM

Super super super exciting!

 

FDA has approved KarXT!

 

First new class of antipsychotic in over 70 years-- since the 1950s with first generation D2s.

KarXT is an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist.

 

 

Big big news!

 

For 70 years there has been this battle between patients and the community -- patients largely become

noncompliant through time because anti-psychotics have severe side-effects. That was largely my 

experience. Sure, I can see the logic in patients taking treatment yet treatment can cause tardive dyskinesia,

it can cause serious brain damage, ...  Really startling that we might now be past that.

 

One might really wonder might happen to homelessness over even the near term. Effective and safe anti-psychotic

treatment might cause a transformative change for those at the most disadvantage in our community. If I were more

in a potentially active psychotic state, having an emergency supply of KarXT as a security blanket might not be a bad

idea.

 

Massively positive news!

 

[Perhaps the only quibble here would be that perhaps the FDA could have diluted the procedure needed to obtain treatment.

Barrier to accessing treatment is a notable feature of schizophrenia. If you could simply go online and make a hassle free purchase,

then it's fine. As soon as you start adding obstacles such as going through the medical establishment in bricks and mortar settings,

it becomes more difficult to connect the patient with the needed treatment.]  

 

 

 

 

 







Also tagged with one or more of these keywords: schizophrenia, alternative medication, self-medication, self-treatment

11 user(s) are reading this topic

0 members, 11 guests, 0 anonymous users